Edgewise Therapeutics Inc is a biotechnology business based in the US. Edgewise Therapeutics shares (EWTX) are listed on the NASDAQ and all prices are listed in US Dollars. Edgewise Therapeutics employs 42 staff and has a market cap (total outstanding shares value) of 0.00.
Our top pick for
Beginners
Our top pick for
Free trades
Our top pick for
Social traders
| Latest market close | $9.60 |
|---|---|
| 52-week range | $5.41 - $22.98 |
| 50-day moving average | $10.25 |
| 200-day moving average | $10.75 |
| Wall St. target price | $24.25 |
| PE ratio | 3.1592 |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $2.89 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $9.6 from 2022-09-29
| 1 week (2022-09-22) | 4.35% |
|---|---|
| 1 month (2022-08-30) | -3.81% |
| 3 months (2022-06-30) | 20.60% |
| 6 months (2022-03-30) | 3.67% |
| 1 year (2021-09-30) | -42.17% |
|---|---|
| 2 years (2020-09-26) | N/A |
| 3 years (2019-09-26) | N/A |
| 5 years (2017-09-26) | N/A |
Valuing Edgewise Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Edgewise Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Edgewise Therapeutics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 3x. In other words, Edgewise Therapeutics shares trade at around 3x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
However, Edgewise Therapeutics's P/E ratio is best considered in relation to those of others within the biotechnology industry or those of similar companies.
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -12.75% |
| Return on equity TTM | -20.76% |
| Profit margin | 0% |
| Book value | $4.95 |
| Market capitalisation | $576.8 million |
TTM: trailing 12 months
We're not expecting Edgewise Therapeutics to pay a dividend over the next 12 months.
Edgewise Therapeutics, Inc. , a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial. It develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado. .
Everything we know about the YanGuFang International Group IPO, plus information on how to buy in.
Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.
A simple guide to buying stocks in your favorite European soccer team.
Steps to owning and managing JUVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing ASR, with 24-hour and historical pricing before you buy.
Steps to owning and managing BVB, with 24-hour and historical pricing before you buy.
Everything we know about the Lead Real Estate Co. IPO, plus information on how to buy in.
Everything we know about the Third Harmonic Bio IPO, plus information on how to buy in.
Everything we know about the LINKBANCORP IPO, plus information on how to buy in.
Here are the stocks that benefit from inflation, as well as industries to keep an eye on to reduce the impacts of inflation on your portfolio.